Mikrobiomik is a biopharmaceutical company, born to research, develop and market medicines based on human microbiota, providing innovative solutions in chronic diseases, currently without cost-efficient alternatives. We want to lead the paradigm change that will involve designing therapeutic solutions based on the human microbiome and be the first company in the world to market the first drug based on fecal microbiota at the U. E, for the indication of recurrence due to Clostridium Difficile.
It is estimated that the microorganisms that inhabit the human body are 100 trillion bacteria, a quadrillion of viruses, fungi, parasites, and archaea. These microorganisms would be 10 times more than the number of human cells and would code for 100 times more genes than our own genome. The normal intestinal microbiota of an adult is composed of between 500 to 1,000 different species of microorganisms.
Faecal microbiota transplantation (FTM) involves the transfer of intestinal microbiota through faecal material from a healthy donor to the gastrointestinal tract of a diseased recipient, with the aim of restoring the balance of the intestinal microbiota. TMF has been shown in multiple clinical trials to be a safe and highly effective procedure in the treatment of recurrent Clostridium Difficile infection.
Mikrobiomik aims to simplify, as much as possible, the transfer of fecal microbiota, avoiding invasive procedures such as colonoscopy, through a simple dosage regimen, based on a single intake of 4 lyophilized capsules of faecal microbiota. The search for new formulations aimed at diseases such as ulcerative colitis or irritable bowel syndrome, will mark the objectives of our R & D in the short term.